Supply of CLIA-Waived Molecular Test Kits (Respiratory Panel)

The contract involves the manufacture and supply of FDA-cleared, CLIA-waived molecular test kits designed for rapid detection of respiratory viruses, including COVID-19, Influenza A/B, RSV, and Strep A. These test kits are compatible with Abbott ID NOW analyzers and are intended for use in point-of-care settings, ensuring quick and accurate diagnostic results. This subcontract opportunity is managed by the Department of Veterans Affairs under the 250-NETWORK Contract Office 10 (36C250) and falls under the NAICS code 325413, which covers pharmaceutical and medicine manufacturing. The solicitation was posted on May 8, 2026, with a response deadline set for May 12, 2026. While specific location details for the office or place of performance were not provided, the contract emphasizes timely delivery of these essential diagnostic tools to support healthcare providers, particularly for veterans’ health services. The project supports ongoing efforts to enhance rapid point-of-care testing capabilities, critical for managing respiratory illness outbreaks efficiently.